Markets

Medtronic's App-based MyCareLink Smart Monitor Wins FDA

An image of people surrounding a sheet of paper with many charts on it
Credit: Shutterstock photo

Medtronic plcMDT recently reported receipt of the FDA approval for its MyCareLink Smart Monitor and subsequent commercial launch of the same in the U.S. Following the news on Nov 17, shares of the company had gained 1.3% to close the session at $77.56 on the subsequent day.

MyCareLink Smart Monitor is the world's first app-based remote monitoring system for implantable pacemakers. According to Medtronic, patients with smartphones or tablets connected through cellular or Wi-Fi service can transmit data from their pacemakers to physicians using app. This, in turn, will aid speedy diagnosis and expedite appropriate treatment decisions. This apart, the device will also facilitate physicians in managing and monitoring their patients implanted with the pacemakers.

MyCareLink Smart Monitor includes a handheld portable device reader and the MyCareLink Smart mobile app that is available free of cost on both Android and iOS. The entire system works on Medtronic's CareLink Network - its remote monitoring service for cardiac device patients, currently used by more than 1 million patients.

With smart appliances promising to make life more convenient for people of all age groups, the launch of such a smart app by Medtronic is indeed well-timed. It should help increase awareness about Medtronic's involvement in remote cardiac monitoring, thereby expanding the company's foothold in this niche.

Overall, at present, the demand for pacemakers is on the rise owing to a growing stroke market. Last quarter, the company witnessed solid growth in this market on the back of increased instances of ischemic stroke and thrombectomy. Going forward, Medtronic expects to see continuation of this growth rate in the range of 25% to 30% worldwide and even higher in the U.S. Hence, the launch of MyCareLink Smart Monitor at this juncture should add further impetus to this growth trend.

Medtronic currently has a Zacks Rank #3 (Hold).

Other Med-Products stocks that warrant a look include GW Pharmaceuticals plc GWPH , Hill-Rom Holdings, Inc. HRC and ICU Medical, Inc. ICUI . All these stocks carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

MEDTRONIC (MDT): Free Stock Analysis Report

GW PHARMA-ADR (GWPH): Free Stock Analysis Report

HILL-ROM HLDGS (HRC): Free Stock Analysis Report

ICU MEDICAL INC (ICUI): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ICUI MDT GWPH HRC

Other Topics

Stocks

Latest Markets Videos